Partner
Recognized as a Global Leader by Intellectual Asset Management's Strategy 300 and as a Next Generation Lawyer by The Legal 500 U.S. for patent litigation, Justin counsels clients on issues of infringement, validity, enforceability, antitrust, unfair competition, licensing, due diligence, and IP portfolio management. He has extensive experience advising clients regarding the interplay between patent and regulatory laws, including Orange Book listing of patents for drugs approved by the Food and Drug Administration (FDA).
Justin regularly speaks on the protection of U.S. intellectual property rights. He has also successfully represented a variety of low-income clients on a pro bono basis.
NOTE: No aspect of these rankings has been approved by the Supreme Court of New Jersey. Further information on methodologies is available via these links.
Selected by his peers as an American Chemical Society Fellow, 2015.
Received the Roger D. Middlekauf Award for outstanding service to the Division of Chemistry and the Law of the American Chemical Society, 2011.
Appointed in December 2008 to serve as deputy general secretary of the Second Beijing International Pharmaceutical and Chemical Intellectual Property Forum in August 2009.
Senju Pharmaceutical Co.; Bausch + Lomb v. Lupin Ltd.
Secured a permanent injunction against generic defendants on behalf of Senju and Bausch + Lomb in Hatch-Waxman patent infringement litigation concerning multiple ANDAs for generic versions of Prolensa®.
1:14-cv-00667, -04149; 1:15-cv-00335; 1:16-cv-01097, D.N.J., Judges Goodman, Shipp, Simandle, Williams
Valeant Pharmaceuticals Int’l, Inc. v. Actavis Laboratories FL, Inc.
Represented Bausch Health Companies (f/k/a Valeant), Salix and Progenics—the innovators and patent owner—in this Hatch-Waxman infringement action in the District of New Jersey. A bench trial was held, and the presiding judge issued an 83-page opinion upholding the validity of the asserted patent claims and finding those claims infringed, thereby entering judgment in favor of plaintiffs through the life of the patents, extending through 2030.
2:16-cv-09038, D.N.J., Judges Chesler, Waldor
BioDelivery Sciences International, Inc. et al. v. Alvogen PB Research & Development LLC et al.
1:18-cv-01395, D. Del., Judge Connolly
Eli Lilly & Co. v. Wockhardt Ltd.
Represented Eli Lilly in Hatch-Waxman patent infringement litigations against several ANDA filers seeking FDA approval to market generic versions of Eli Lilly's Cymbalta®. The S.D. Indiana entered judgment before trial in favor of Eli Lilly and against all the ANDA filers on all issues, resulting in orders and judgment maintaining Cymbalta's® market exclusivity through the end of its patent life.
1:08-cv-01547, S.D. Ind., Judges Baker, Lawrence, Pratt
Total Rebuild Inc. v. PHC Fluid Power, LLC
6:15-cv-01855, W.D. La., Judge Doughty
Salient Systems Corporation v. Hawk Technology Systems LLC et al.
1:20-cv-01558, D. Del., Judge Connolly
At the PTAB Blog
Petitioners Fail on Inherency but Prevail on Obviousness Petitioners Fail on Inherency but Prevail on Obviousness
February 9, 2024
Event
Inducement to Infringe in Hatch-Waxman Litigation: Strategies for Patent Drafting, Prosecution, and Litigation Inducement to Infringe in Hatch-Waxman Litigation: Strategies for Patent Drafting, Prosecution, and Litigation
December 14, 2023
Webinar
Event
Center for Intellectual Property x Innovation Policy Fall Conference Center for Intellectual Property x Innovation Policy Fall Conference
October 12-13, 2023
Arlington
At the PTAB Blog
§ 112(a) Is a Priority in Decision to Institute IPR; Did Not Work to Say Petitioner Should Have Filed a PGR § 112(a) Is a Priority in Decision to Institute IPR; Did Not Work to Say Petitioner Should Have Filed a PGR
August 23, 2023
Award/Ranking
10 Finnegan Attorneys Named to the 2023 IAM Strategy 300 List 10 Finnegan Attorneys Named to the 2023 IAM Strategy 300 List
October 5, 2023
Intellectual Asset ManagementMedia Mention
Litigator of the Week Runners-Up and Shout Outs: Castle Retail Group Litigator of the Week Runners-Up and Shout Outs: Castle Retail Group
February 24, 2023
The AmLaw Litigation DailyPress Release
Finnegan Victory for BioDelivery Sciences International in ANDA Case Affirmed Finnegan Victory for BioDelivery Sciences International in ANDA Case Affirmed
December 29, 2022
Media Mention
Del. Judge Upholds Claims in Opioid Drug IP But Axes Others Del. Judge Upholds Claims in Opioid Drug IP But Axes Others
December 20, 2021
Law360Media Mention
Actavis Infringed Constipation Drug Patent, Judge Rules Actavis Infringed Constipation Drug Patent, Judge Rules
July 22, 2019
Law360Press Release
Finnegan Receives the Most Tier 1 IP Rankings in The Legal 500 U.S. Guide Finnegan Receives the Most Tier 1 IP Rankings in The Legal 500 U.S. Guide
May 30, 2018
The Legal 500Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.